The Clinical Trials Research Unit (CTRU) at the University of Leeds has developed a series of webinars for researchers and clinicians about the UKMRA-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma clinical trials.
CARP is a research initiative funded by Myeloma UK that focuses on the development of early phase myeloma trials. It also gives early career researchers or clinicians seeking trials experience the opportunity to get advice and develop their skills with the expertise and support of the UK Myeloma Research Alliance and the University of Leeds Clinical Trials Research Unit.
The webinars provide information about why CARP was created, how it can help researchers develop early phase trials and provide details of what is involved in early phase trial design. The speakers are senior trialists and patient representatives who are all actively involved in CARP. Each one-hour session will consist of 30-45 minutes of presentation(s) followed by Q&A.
Developing early phase myeloma research in the UK: an introduction to the UKMRA-MUK-Concept and Access Research Programme
Recorded on 25 March 2021
Prof. Gordon Cook, Clinical Director (Haematology) Clinical Trials Research Unit, provides an overview of early phase myeloma trials in the UK.
Sarah McDonald, Director of Research at Myeloma UK, shares her thoughts on the importance of early phase research.
Dr Sarah Brown, CARP lead, Associate Professor at the University of Leeds Clinical Trials Research Unit, discusses the practicalities of developing an early phase clinical trial proposal through CARP.
Implementation of an early phase myeloma platform trial
Recorded on 29 April 2021
Dr Rakesh Popat, Consultant Haematologist and Honorary Associate Professor at University College London Hospital, shares his experiences of developing and setting up an early phase myeloma clinical trial through CARP.
Public and patient involvement and engagement in clinical trials
Recorded on 24 June 2021
Holly Schofield, Public and Patient Involvement and Engagement Lead at Leeds CTRU and Dr Sandra Quinn, Health Services Research Manager at Myeloma UK, discuss how to involve patients when developing and designing research studies.
Early career experiences of clinical trials research – clinical and academic perspectives
Recorded on 22 July 2021
Dr Charlotte Pawlyn, Consultant Haematologist at The Institute of Cancer Research, London and Dr Christopher Parrish, Consultant Haematologist at St James’s Hospital, Leeds share their experiences of clinical trials research.
They talk about the ways you can join trial management groups and ultimately lead a clinical trial. You can learn about clinical and academic pathways, and the roles both Charlotte and Chris have played in the UKMRA-Myeloma UK CARP research programme.
Register now on Eventbrite.
Phase I, dose-finding studies in myeloma – A practical overview of design
Recorded on 23 September 2021
Statistician Andrew Hall discusses the practical aspects in designing Phase I dose-finding trials in myeloma. He describes the aims and objectives of dose-finding studies as well as the traditional approach and its shortcomings. He also talks about how the model-based designs used within CARP improve upon traditional trial designs and how modern treatments may require a slightly different approach to trial design.
Highlights from ASH
Recorded on 10 February 2022.
Prof. Gordon Cook, Clinical Director (Haematology) Clinical Trials Research Unit, will give an overview of key myeloma data presented at the ASH 2021 conference.
OPTIMUM/MUK9 results presentation
Recorded on 8 March 2022.
Dr Martin Kaiser, Chief Investigator for OPTIMUM/MUK nine trial presents the primary endpoint results from the trial which evaluates the use of daratumumab, cyclophosphamide, bortezomib, lenalidomide and dexamethasone as induction and extended post-transplant consolidation for patients with ultra-high risk myeloma.
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: Results of the MUKeight trial
Recorded on 16 June 2022.
Dr Holger Auner presents results from the MUK eight trial. This phase 2 trial evaluated the use of ixazomib in combination with cyclophosphamide and dexamethasone in patients with relapsed/refractory myeloma.